Construction and multiple validations of a robust ferroptosis-related prognostic model in bladder cancer: A comprehensive study

Xianyu Dai,Kai Yu,Hongjie Wang,Rong Zhong,Zhongqi Zhang,Yuchuan Hou

DOI: https://doi.org/10.1097/md.0000000000040133

IF: 1.6

2024-10-30

Medicine

Abstract:Bladder cancer (BC) is common and has a poor prognosis. It results from genetic and environmental factors and can be categorized into 2 subtypes based on invasion degree: muscle-invasive bladder cancer (MIBC) and non-MIBC (NMIBC). [ 1 ] BC incidence rate ranks 9th globally among all malignancies, [ 2 ] with approximately 550,000 new cases and 200,000 deaths annually. [ 3 ] In 2021, the United States reported 84,000 new BC cases and 17,000 BC deaths. [ 4 ] According to incomplete statistics, BC incidence in males is 9.6 per 100,000, with a death rate of 3.2 per 100,000. In contrast, BC incidence in females is approximately one-quarter that of males. [ 3 ] Patients with NMIBC account for nearly 75% of newly diagnosed cases. After standardized treatment following clinical guidelines, 70% may experience recurrence, while 15% may progress. Approximately 25% of patients are diagnosed with MIBC, mostly primary invasive BC, with poor prognosis. [ 5 ] Various treatment methods for BC exist, including radical cystectomy and transurethral resection of bladder tumors, followed by intravesical instillation therapy, chemotherapy, immunotherapy, and targeted therapy. [ 5 ] Intravesical instillation comprises chemotherapy drugs, such as epirubicin, immunotherapy drugs, such as BCG, and targeted functional nanomedicines that have become popular in recent years. [ 6 ] The clinical treatment of patients with BC is often costly because of its inherently high recurrence rate and frequent intravesical perfusion, [ 7 ] aggravating the burden on patients and the social economy. In general, the prognosis of patients with BC is often associated with clinical and pathological staging, [ 8 , 9 ] which holds some significance in predicting prognosis but cannot explain why patients with the same clinical and pathological staging have different outcomes. [ 10 ] Therefore, identifying novel biological signatures valuable for the prognosis of patients with BC and building a novel risk prediction model using data mining and bioinformatics analysis are urgent.

medicine, general & internal